Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Baxter International Inc. is a global medical products and healthcare company focused on providing essential therapies and technologies used in hospitals, clinics, and home-care settings. The company operates primarily within the medical devices, pharmaceuticals, and renal care industries, supplying products that support critical care, nutrition, kidney disease treatment, and medication delivery. Baxter’s offerings are designed to sustain life and improve clinical outcomes for patients with chronic and acute conditions.
The company’s primary revenue drivers include sterile intravenous (IV) solutions, infusion systems, renal therapies, parenteral nutrition, and acute care pharmaceuticals. Baxter serves hospitals, dialysis centers, clinicians, and home-care providers, with a strong emphasis on recurring demand for consumable medical products. Founded in 1931, Baxter evolved from a small IV solutions manufacturer into a diversified global healthcare supplier through internal innovation, international expansion, and targeted acquisitions, positioning itself as a key provider of mission-critical hospital products.
Business Operations
Baxter generates revenue through several core operating segments, most notably Medical Products and Therapies, which includes IV solutions, infusion pumps, administration sets, and parenteral nutrition products, and Pharmaceuticals, which encompasses injectable drugs, anesthetics, and premixed medications. The company also maintains a significant presence in Renal Care, delivering dialysis machines, peritoneal dialysis solutions, and related services for patients with end-stage renal disease.
Operations span both domestic and international markets, with manufacturing facilities, R&D centers, and distribution networks across multiple continents. Baxter controls proprietary drug formulations, sterile manufacturing technologies, and regulated medical device platforms that create high barriers to entry. The company operates through numerous wholly owned subsidiaries and has historically engaged in partnerships with hospitals, group purchasing organizations, and healthcare systems to ensure long-term supply relationships.
Strategic Position & Investments
Baxter’s strategic direction centers on strengthening its core hospital and renal care franchises, improving operational efficiency, and investing in innovation for critical and chronic care. Growth initiatives include product line extensions in infusion therapy, next-generation dialysis technologies, and expanded pharmaceutical portfolios focused on hospital-administered medications.
The company has pursued selective acquisitions and divestitures to refine its focus on higher-margin, clinically essential products. Notable strategic actions in recent years include the acquisition of Hillrom Holdings, Inc., which expanded Baxter’s footprint into connected care, patient monitoring, and hospital equipment, as well as investments in digital health capabilities to integrate data-driven insights into care delivery. Baxter also continues to invest in automation, advanced manufacturing, and supply chain resilience following global healthcare disruptions.
Geographic Footprint
Baxter is headquartered in North America, with its corporate headquarters located in the United States, and maintains a broad international presence. The company operates in more than 100 countries, with significant market presence across Europe, Asia-Pacific, Latin America, and Middle East & Africa, supporting a globally diversified revenue base.
Manufacturing and distribution facilities are strategically located to serve regional healthcare systems and comply with local regulatory requirements. International operations contribute a substantial portion of overall revenue, and Baxter’s global footprint enables it to participate in both developed and emerging healthcare markets, particularly in regions experiencing rising demand for hospital infrastructure and chronic disease management.
Leadership & Governance
Baxter is led by an experienced executive team with deep backgrounds in healthcare, medical technology, and global operations. The leadership emphasizes a strategy focused on patient safety, operational excellence, and long-term value creation through innovation and disciplined capital allocation.
Key executives include:
- José E. Almeida – Chairman of the Board and former Chief Executive Officer
- Brent Shafer – Chair and Interim Chief Executive Officer (as of publicly available disclosures)
- Heather Knight – Executive Vice President and Chief Operating Officer
- Andrew Hider – Executive Vice President and Chief Financial Officer
- Lisa Edwards – Executive Vice President and President, Medical Products and Therapies
The company operates under a governance framework aligned with U.S. public company standards, with oversight provided by an independent board of directors and disclosures governed by SEC filings, including annual and quarterly reports.